TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

Cited by papers we hold 17

• Cold and hot tumors: from molecular mechanisms to targeted therapy · 2024
  No notice
• Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives · 2024
  No notice
• Immunotherapy: a promising approach for glioma treatment · 2023
  No notice
• Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials · 2023
  Corrected
• Immunotherapy for glioblastoma: the promise of combination strategies · 2022
  No notice
• Natural killer cells: a promising immunotherapy for cancer · 2022
  No notice
• Immune Checkpoint Inhibitors in Human Glioma Microenvironment · 2021
  No notice
• Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers · 2021
  No notice
• TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer · 2021
  No notice
• NK Cell-Based Immune Checkpoint Inhibition · 2020
  No notice
• The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity · 2020
  Corrected
• Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors · 2020
  No notice
• Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors · 2020
  No notice
• The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response · 2019
  No notice
• PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells · 2019
  No notice
• Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer · 2019
  No notice
• Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.